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ABSTRACT OF THE THESIS 
 
Metabolic analysis of single cell gene expression data:  
What can we learn? 
 
 
 
by 
 
Yuchen Zhou 
 
Master of Science in Bioengineering 
 
University of California San Diego, 2020  
 
Professor Bernhard Ø. Palsson, Chair 
 
The advent of single cell profiling technologies has brought unprecedented 
resolution to cell heterogeneity in key human tissues. A significant remaining challenge 
is to interpret this cell variation in terms of meaningful functional differences and 
interactions between cell types. In this study, we perform a metabolic reconstruction-
                                                                          ix  
based assessment of transcriptional heterogeneity in the human brain and kidney. We 
focus specifically on transporters as their expression is associated with both metabolic 
interactions between cell types and uptake of drugs. We find that: 1) we are able to 
identify drug-transporter relationships through structural homology between drugs and 
native transporter substrates, 2) we observe concomitant brain-region specific 
expression differences in key transporters that may impact therapeutic impact, 3) 
upstream metabolic genes have expression that correlates with the transporter 
expression, suggesting that transporter differences are likely physiologically significant, 
4) examination of kidney data shows differential expression across different regions and 
cell types in the human kidney, 5) metabolic reconstructions provide useful 
interpretation to help understand the significance of single cell gene expression 
differences. Native metabolic activity of transporters is postulated through expression of 
metabolic genes with activities that are correlated as determined by metabolic flux 
modeling. This work illustrates the types of higher order interactions that can be 
elucidated from single cell profiling data and paves the way to clinical interventions 
targeting particular cell types and cell interactions. 
 
 
 
 
1 
INTRODUCTION 
With rapid improvements to single-nucleus RNA sequencing methods, we are 
now gaining an increasingly clear picture of the differences in gene expression data 
between single cells in human tissues (Lake et al. 2017, 2016). Large scale single-cell 
expression data sets are now available for the human brain (Lake et al. 2016) and 
kidney (Lake et al. 2019). These studies have novel cell subtypes that exist in specific 
organ regions with defined physiological functions. The natural subsequent question is 
to determine whether differential expression of particular genes in certain cell subtypes 
can be linked to the phenotypes exhibited by these organ regions, which may include 
such features as healthy physiological functions or response to drug treatment. 
There are many methods to understand high-dimensional biological data, for 
example statistical analysis and pathway analysis. One of the most successful methods 
for linking statistical differences to organism functions has been through the use of 
metabolic reconstructions. Metabolic reconstructions are carefully curated 
knowledgebase consisting of all known metabolic functions within an organism (Thiele 
and Palsson, 2010). These reconstructions serve as a platform to integrate various 
disparate data types to relate them quantitatively through network structure and 
function. The human metabolic network has been reconstructed and gradually improved 
over several iterations, culminating in the latest version Recon3D (Brunk et al. 2018). 
Analysis of transporters specifically has a number of advantages. In the human 
brain and kidney, transporter activities, either neurotransmitter exchanges or filtration 
activities, are critical organ functions. Furthermore, it has been proposed that 
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transporters, as opposed to passive diffusion, may be responsible for a significant 
amount of drug uptake (O Hagan et al. 2015; Kell 2016). It was shown that similarities 
between endogenous metabolites in human tissues and drugs can be established via 
molecular fingerprints. Based on transporter expression, we may become able to 
determine region and cell specific targeting by drugs based on similarity to native 
compounds expressed by different cells. Last, we may begin to hypothesize metabolic 
interactions between different cell types co-localized in specific tissue or organs. 
In this study, we collect native metabolite structures for all reconstructed human 
metabolites and single cell gene expression data for both human brain and kidney. Data 
on drug structures and known transporters are also collected in full from DrugBank 
(Wishart et al. 2008). We then compare pairwise structure similarity between natural 
metabolites and marketed drugs. Transporter expression data in each cell type are 
analyzed via machine learning methods for both the human brain and kidney. We then 
identify associations between particular transporters, metabolic functions, and likely 
region-specific drug uptakes. This work seeks to establish how metabolic 
reconstructions and chemical structural data can be combined with single-cell 
expression data to generate new hypotheses about the physiological role of newly 
identified cell subtypes. 
 
 
 
 
3 
METHODS 
 
2.1. Extraction of transporter information from a human metabolic network 
reconstruction 
To get the list of all transporter reactions, we use the Recon3D model from BiGG 
(bigg.ucsd.edu), which is the latest human metabolic network reconstruction. Then by 
using the Constraints-Based Reconstruction and Analysis (COBRA) approach, we 
extract a list of all transporter reactions that involve a same metabolite in both the 
extracellular compartment and the cytosol compartment from the Recon3D model. This 
transporter reactions list becomes the basis of the next steps. From the Recon3D 
model, the mapping of reactions, metabolites, and metabolite structures to the 
transporters is generated.  
 
2.2. Extraction of drug information from DrugBank 
On the other hand, the structures of all marketed drugs are obtained from 
DrugBank (drugbank.ca). We download the full drug structure links file that includes 
drug IDs, names, groups, proved transporters, and different systems of drug structures 
including general chemical formula, International Chemical Identifier (InChI), and 
Simplified Molecular-input Line-entry System (SMILES). To keep consistency and go 
through appropriate analysis, we use canonical SMILES structure from PubChem 
(pubchem.ncbi.nlm.nih.gov) for each metabolite and drug.  
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2.3. Calculation of structural similarity between drugs and native metabolites 
Based on the structure links, we are able to calculate the similarity pairwise 
between native compounds and drugs based on Tanimoto coefficient of chemical 
fingerprints using RDKit, a universal toolkit for cheminformatics. A total of 1347 native 
compounds involved in transporter reactions and 9288 drugs are compared pairwise. By 
this calculation, we generate a similarity matrix and are able to identify drugs that are 
more similar to metabolites and to see if they tend to be transported by the same 
transporters. The similarity matrix also helps to explore drug-metabolite-transporter 
associations. 
 
2.4. Analysis of single cell gene expression data of human brain and kidney 
We obtained the gene expression data on a single cell basis for the human brain 
and kidney from Professor Kun Zhang’s laboratory at UCSD. Nuclei substances were 
extracted from pre-operated cryosection from different regions in human brain. Single-
nucleus assays were then run to measure the expression values in each cell and collect 
cell-type-specific expression data sets. We proceeded to analyze the data using 
machine learning methods. In order to compare the similarity of the drug to compound 
among several different dimensions, such as drugs and compounds share a transporter 
versus not sharing a transporter, transporters that proved to transport a specific drug 
versus not transport that drug, and transporters in different families involved membrane 
reactions, we use box and whisker plot to show the comparisons. Also, to provide 
validation, we use receiver operating characteristic (ROC) curves to predict drug-
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transporter associations in binary class based on similarity values. ROC curves 
examine the diagnostic ability of a binary classifier system, and a higher score implies 
higher diagnostic ability of the system. To see the trend of single cell gene expression in 
human brain and kidney, we plot the expression heatmaps between transporter genes 
and cell types using Matplotlib in python. We also analyze the data via scikit-learn 
packages (sklearn) to group and cluster the dataset, and plot graphs using Matplotlib. 
After trying k-mean, Principal Component Analysis (PCA), and t-Distributed Stochastic 
Neighbor Embedding (TSNE), and calculating silhoutte coefficients for k-mean to 
visualize high-dimensional datasets, we choose TSNE clustering method to illustrate the 
results, since it shows the most distinctive clustering results. For each dataset, we test 
perplexity from 1 to 100, and choose the most appropriate value for each graph. 
 
2.5. Analysis of upstream metabolic gene expression 
 To combine the human brain gene expression data with human metabolic 
network reconstruction, we use Escher (escher.github.io) to visualize biological 
pathways with correlated genes, proteins, enzymes, and reactions. Recon3D model 
provides a full human metabolic network to generate the biological pathway map. We 
use metabolic modeling as our tools to identify pathways linked to transported 
metabolites with a focus on neurotransmitters that are clearly defined metabolic 
functions of brain cells. We also use metabolic modeling method to explore the 
correlation between excitatory and inhibitory neurotransmitter gene expression.  
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RESULTS 
 
3.1. Analysis of drug-transporter associations 
To explore drug-transporter associations, we calculate drug-metabolite structural 
similarities via Tanimoto coefficient, and then link the drugs to particular transporters 
through the native activity of these transporters. We hypothesize that higher similarity 
scores imply co-transportation of native compound and drug. We use two native 
metabolites, 2-oxoglutarate (akg) and triiodothyronine (triodthy), as examples, and 
calculate the similarity scores for all drugs that share a transporter to the metabolites, 
respectively, as shown in Figure 1. According to the figure, drugs and metabolites 
transported by different transporters have similar scores. 
 
Figure 1.1: Tanimoto similarity scores of all the drugs that share transporters with 
metabolite akg (2-oxoglutarate), different transporters in different colors 
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Figure 1.2: Tanimoto similarity scores of all the drugs that share transporters with 
metabolite triodthy (Triiodothyronine), different transporters in different colors 
 
Figure 2 shows a set of box and whisker plots in order to broadly compare 
similarity of the drug to compounds that share a transporter versus not sharing a 
transporter. Figure 2.1 is the comparison of all the drugs sharing the transporter 
SLCO1B1 to all of the metabolites known to be transported by SLCO1B1, with each box 
indicating the average similarity value of all the metabolites compared to the specific 
drug. Figure 2.2 shows an example case of the drug Methotrexate, comparing all 
metabolites to the drug Methotrexate versus each transporter known to transport 
Methotrexate individually, each with the metabolites known to be transported by the 
transporter independently.  With an average similarity value 0.37 of all the native 
compounds comparing to Methotrexate, the average similarity values of all the native 
compounds transported by transporter SLC22A11, SLC19A1, and SLC46A1, 
separately, are much higher, providing evidence that drugs and metabolites transported 
by these three transporters are more similar. The gene SLC19A1 encodes membrane 
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protein that serves as a transporter of folate and is involved in the regulation of 
intracellular concentrations of folate. This is consistent with the high similarity value 0.78 
between methotrexate and folate. Figure 2.3 shows an example case of the drug 
Zidovudine, comparing all metabolites to Zidovudine versus each transporter known to 
transport Zidovudine individually, each with the metabolites known to be transported by 
the transporter independently.  With an average similarity value 0.38 of all the native 
compounds comparing to Zidovudine, the average similarity values of all the native 
compounds transported by transporter SLC29A2 and SLC28A1, separately, are much 
higher, providing evidence that drugs and metabolites transported by these two 
transporters are more similar. The transporter SLC28A1 is associated with Acquired 
Immunodeficiency Syndrome (AIDS), and the drug Zidovudine is one of the treatments 
for AIDS. This result validates that highly similar metabolites and drugs can be co-
transported by a transporter that has similar function to the drug. 
 
Figure 2.1: Comparison of the drugs sharing the transporter SLCO1B1 to all of the 
metabolites known to be transported by SLCO1B1 
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Box and Whisker Plot of Metabolite vs. Drug Similarity                    
 
Figure 2.2: Comparison of all metabolites to Methotrexate versus each transporter 
known to transport Methotrexate individually, each with the metabolites known to be 
transported by the transporter independently 
 
Box and Whisker Plot of Metabolite vs. Drug Similarity 
 
Figure 2.3: Comparison of all metabolites to Zidovudine versus each transporter known 
to transport Zidovudine individually, each with the metabolites known to be transported 
by the transporter independently 
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Then we compare transporters in solute carrier family (SLC) to transporters not in 
SLC family, each with the metabolites known to be transported by the transporter 
independently. Figure 2.4 indicates that the drug-metabolite similarity values are higher 
when transported by transporters in SLC family than in non-SLC family. An explanation 
is that SLC genes encode more membrane-bound proteins that facilitate more 
membrane transportations and have better co-transporting ability. 
 
 
Figure 2.4: Comparison of transporters in SLC family to transporters not in SLC family, 
each with the metabolites known to be transported by the transporter independently 
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3.2. Prediction of drug-transporter relationships based on structural similarity 
We use receiver operating characteristic (ROC) curves as a validation to predict 
drug-transporter associations based on similarity values and choose a cutoff value from 
0.58 to 1. As shown in Figure 3, the area under the ROC curve is 0.85, proving that we 
are predicting the most likely transporters by comparing drugs to native metabolites. 
 
Figure 3.1: Receiver Operating Characteristic (ROC) curve for drug-metabolite 
associations based on Tanimoto Similarity values (drug-transporter pairs from 
supplementary table 1 of Dobson and Kell’s paper, 2008) 
 
 
Figure 3.2: More ROC curves extended to multiclass 
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We also test drug transporter expression across cell types, and have four 
example drugs as case studies, including Methotrexate, Zidovudine, Benzylpenicillin, 
and Rosuvastatin. As shown in figure 4, for Methotrexate, cell End have the highest 
expression across transporter types, and transporter SLCO3A1 shows the highest 
expression across cell types, which has brain indication from DrugBank to treat Soft 
Tissue Sarcoma (STS). For Zidovudine, cell End also shows the highest expression 
value, and transporter ABCC5 has the highest expression value across cell types. For 
Benzylpenicillin, cell End and Mic have higher transporter expression, and transporter 
SLCO3A1 shows the highest expression across cell types. Lastly, for Rosuvastatin, cell 
End, Ast, and Oli has higher expression values, and transporter ABCC1 has the highest 
expression across cell types. This set of results indicates that compared to excitatory 
and inhibitory neurons in human brain, non-neural cells show much higher expression 
values of the transporter genes. Some transporter such as SLCO3A1, with high 
expression values in different types of brain cells, is proved to be efficient to treat 
specific brain-related diseases. 
 
Figure 4.1: Average expression values of transporter genes known to transport 
Methotrexate across 21 cell types 
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Figure 4.2: Average expression values of transporter genes known to transport 
Zidovudine across 21 cell types 
 
 
Figure 4.3: Average expression values of transporter genes known to transport 
Benzylpenicillin across 21 cell types 
 
 
Figure 4.4: Average expression values of transporter genes known to transport 
Rosuvastatin across 21 cell types 
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3.3. Analysis of transporter gene expression in the human brain at single-cell resolution 
 We first calculate average expression values of transporter genes for 21 cell 
types. Figure 5 shows the simple mapping of expression data to transporters for each 
cell type. The resulting heatmaps indicate that cell type Ex5, Ast, and End have 
differentially expressed transporter data. We also use TSNE clustering method to 
illustrate transporter expression across different genes and cell types (Figure 6). 
Although the 21 cell types are functionally classified into three categories (excitatory 
neurons, inhibitory neurons, and non-neural cells), the clustering patterns based on 
transporter expression alone does not show a clear distinction between the cell types.  
 
Figure 5: Average expression values of transporter genes for each brain cell type 
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          TSNE Projection of 21 cell types 
 
Figure 6.1: TSNE plot of 21 cell types (perplexity = 2) 
 
                     TSNE of 237 transporters 
 
Figure 6.2: TSNE plot of 237 genes/transporters (perplexity = 10) 
 
 
3.4. Analysis of single-cell gene expression data for the human kidney 
We have similar analysis for kidney transporter expression and cell-specific 
metabolite transport data. The 30 cell types measured for expression data are from 
different functional structures in adult human kidney (Lake et al. 2019). Figure 7 collects 
the mapping and clustering results for the kidney data. After biclustering the data, a 
clear pattern shows up in Figure 7.2. We can easily classify the transporters into three 
16 
categories: variable expression, cell subtype-linked expression, and uniform expression 
pattern. By visiting the original data and kidney anatomy image, we can conclude that 
the transporters have higher expression values in proximal tubules, glomerular 
capsules, descending thin limb, and thin ascending limb. 
 
Figure 7.1: Average expression values of transporter genes for each kidney cell type 
(log scale) 
 
 
Figure 7.2: Biclustering structure of rearranged data 
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Figure 7.3: Hierarchical Clustering of kidney data (30 cell types, 6 clusters) 
 
Due to the more complicated structure than human brain and various cell types in 
human kidney, the results are more complex for analyzing and identifying related kidney 
diseases. Despite the latest expression data for human kidney, scientists can hardly 
ethically gain normal kidney tissue source from human. With better tested data in the 
future, we can go further towards the molecular metabolic analysis and physiological 
organization of human kidney.  
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DISCUSSION 
In this work, we sought to determine whether we could use metabolic network 
reconstructions and chemical structure information to empower the analysis of human 
single-cell gene expression data. 
A key hypothesis underlying the analysis in this study was the postulation that 
transporters, rather than passive diffusion, may be responsible for the majority of drug 
uptake in tissues. We used similarity of drugs to native transported substrates to predict 
possible drug transporters. During this analysis, it became clear that assigning cutoffs to 
similarity was difficult. In comparison to experimentally validated drug transporters, 
certain transporters were validated while others did not mean a similarity cutoff to their 
native substrate. A key limiting factor was the small number of validated transporters, 
and importantly negative samples where a drug was established as not being 
transported. Such cases may help to establish relevant cutoffs for similarity required for 
shared transport activity.  
Due to limited data on experimentally-determined drug transporters, assessment 
of transporters linked to drugs was dependent upon a structural comparison to native 
transporter substrates. It is clear that the chemical fingerprints, as well as the Tanimoto 
coefficient calculated thereafter, are not ideal metrics for predicting likelihood of sharing 
a transporter. The most successful predictions were the trivial cases where the drug is a 
substrate analog of the native transporter substrate. However, chemicals can share a 
transporter with much more diverse structures, for example, transporters that can 
recognize a broad array of amino acids with substantial structural differences. It is 
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possible that a moiety-based similarity metric may be more useful, but such a metric is 
more difficult to develop and requires its own testing (O’Hagan and Kell 2017). 
 Through integration of single-cell gene expression data with drug transporter 
predictions, we sought to identify subtypes of cells or regions of tissue that would be 
preferentially affected by certain drugs. This requires identification of transporter 
expression patterns tied to cell subtypes. Surprisingly, the cell subtypes did not clearly 
cluster into particular transporter expression patterns, despite largely sharing from a few 
neurotransmitter use patterns. It is possible that non-neurotransmitter-related 
transporters dominate the clustering, and expression of these genes is more 
heterogeneous. Further analysis of particular subtypes or regions affected by drugs was 
largely prospective; very little experimental data was found on regions of the brain 
affected by drugs. This may be a fruitful avenue for more investigation for example by 
comparing to fMRI analysis during drug treatment. Additionally, we wanted to identify 
native metabolic functions of these cell types. A complication here is the fact that many 
transporters can transport multiple substrates, thus the relevant metabolic activity is not 
clear. We can additionally examine expression of genes upstream from each possible 
transported native substrate, which has proven helpful when examining 
neurotransmitter pathways for example (Wandschneider and Koepp 2016). Finally, 
examination of kidney data showed differential expression across different regions and 
cell types. This contributes to further analysis of kidney anatomy and functional region 
identifications.  
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In summary, the work presented gives sufficient support for further examination 
of the integration of chemical structures, metabolic networks, and single-cell gene 
expression. A key next step will be gathering experimental data to validate predicted 
phenotypes tied to particular organ regions and cell subtypes, as well as histological 
relationships between cell subtypes that may better inform likely metabolic interactions. 
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